The Lancet Infectious Diseases Publication
We are delighted to announce that our paper “Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for Drug-sensitive and Drug-resistant Pulmonary Tuberculosis treatment – a phase 2c, open-label, multicentre, partially randomised controlled trial” was accepted for publication in the Lancet. This has been achieved through the efforts of the whole consortium a mammoth achievement, depending as it does, on the efforts of every member who has participated in delivering the trial.
The full article can be accessed here:
https://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(24)00223-8.pdf